DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.


Berkeley Heights, NJ – April 11, 2019 – CorMedix Inc. (NYSE American: CRMD), a
biopharmaceutical company focused on developing and commercializing therapeutic products
for the prevention and treatment of infectious and inflammatory disease, today announced that
on Friday, April 5, 2019, the NYSE American notified CorMedix that the company had regained
compliance with the NYSE American listing requirements because the company has resolved the
continued listing deficiency with respect to Section 1003(a)(i), Section 1003(a)(ii) and Section
1003(a)(iii) of the NYSE American Company Guide.

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing
therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic
antimicrobial solution designed to prevent costly and dangerous bloodstream infections
associated with the use of central venous catheters, currently in Phase 3 development for
patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system
approximately $6 billion annually and contribute significantly to increased morbidity and
mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease
Product, which provides the potential for priority review of a marketing application by FDA and
allows for 5 additional years of QIDP market exclusivity in the event of U.S. approval. Neutrolin is
already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix
is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices,
with active programs in surgical sutures and meshes, and topical hydrogels. The company is also
working with top-tier researchers to develop taurolidine-based therapies for rare pediatric
cancers. For more information, visit:

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All
statements, other than statements of historical facts, regarding management’s expectations,
beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future
revenues and projected costs should be considered forward-looking. Readers are cautioned that
actual results may differ materially from projections or estimates due to a variety of important
factors, including: the resources needed to terminate the Phase 3 trial and the costs and time
needed to submit a new drug application to the FDA; the risks and uncertainties associated with
CorMedix’s ability to manage its limited cash resources and the impact on current, planned or
future research, including the continued development of Neutrolin and research for additional
uses for taurolidine; obtaining additional financing to support CorMedix’s research and
development and clinical activities and operations; risks related to obtaining FDA approval of the
new drug application for Neutrolin; relying on preclinical results that may not be indicative of
success in clinical trials and might not be replicated in any subsequent studies or trials; and the
ability to retain and hire necessary personnel to staff our operations appropriately. These and
other risks are described in greater detail in CorMedix’s filings with the SEC, copies of which are
available free of charge at the SEC’s website at or upon request from CorMedix.
CorMedix may not actually achieve the goals or plans described in its forward-looking
statements, and investors should not place undue reliance on these statements. CorMedix
assumes no obligation and does not intend to update these forward-looking statements, except
as required by law.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors